p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases.
- 1 January 2004
- journal article
- Published by Springer Science and Business Media LLC in Clinical & Experimental Metastasis
- Vol. 21 (1), 79-85
- https://doi.org/10.1023/b:clin.0000017206.08931.42
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.2002
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significanceBritish Journal of Cancer, 1998
- Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumorsAnnals of Surgical Oncology, 1996
- p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Human Tumor Antigens Are Ready to FlyAdvances in Immunology, 1996
- Express Yourself or Die: Peptides, MHC Molecules, and NK CellsScience, 1995
- Factors influencing the natural history of colorectal liver metastasesThe Lancet, 1994
- Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrenceInternational Journal of Cancer, 1991
- Loss of HLA‐A,B,C and de novo expression of HLA‐D in colorectal cancerInternational Journal of Cancer, 1986